Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2003

View Archived Issues

Phase I interim safety data reported for Reolysin in malignant glioma

Results reported for NBI-3001 in glioblastoma

Cytogen regains rights to ex vivo prostate cancer immunotherapy

Velcade enters phase II trial in colorectal cancer

MoliChem reacquires rights to Moli-1901

AEterna acquires Zentaris from Degussa

Zindaclin receives further E.U. approvals

NexMed completes dosing in two-year rat carcinogenicity study

Crucell regains rights to anti-CD46 antibody

IND filed for EOS-200-4

Topamax sNDA submitted for migraine prevention

Xenova advances two new programs into preclinical research

Restasis receives FDA approval

Amylin to acquire rights to Restoragen's GLP-1 program

Inspra meets primary endpoints in EPHESUS trial

COX-2-specific inhibitor LAS-34475 compares favorably to naproxen in osteoarthritis

HDAC inhibitor MS-275 active against pediatric solid tumors in vitro and in vivo

Third phase III MorphiDex trial fails to meet endpoints

Pharmacokinetic, toxicity and efficacy data for LEraf-AON in animals

Highly selective CB2 receptor ligand emerges from SAR studies at U.S. universities

New central muscle relaxant/antiinflammatory/analgesic advanced to clinical evaluation at GSK

Novel caspase inhibitors and their use reported by Vertex

Anticonvulsant compounds in early development at UCB

Ono patent covers new endothelial differentiation gene-1 (EDG1) agonists

New JAK3 inhibitors identified at AstraZeneca

Nonredox antiobesity cobalt porphyrin complexes discovered at MitoKor

Modified antisense oligonucleotides targeting ICAM-1 and VCAM-1 show potential in IBD

Galderma describes new series of vitamin D analogues for skin disorders